ClinicalTrials.gg
RecruitingNCT06074848tDCSUpdated Apr 24, 2024

tDCS in the Management of Post-COVID Disorders

A Phase 2 interventional study of Transcranial Direct Current Stimulation (tDCS) and Motor Training in Long COVID, sponsored by Universidade Federal de Pernambuco. Recruiting at 2 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Universidade Federal de Pernambuco · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil — 9 open to participants now, 10 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Brazil.

Planned enrollment
11th of 18
48 · median 57
Started
2023
with 5 others
Phase 2
3 of 21
1 open now
Registered
10th of 21
by date

Among the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, this one is the 11th largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 2, and was the 10th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

9 of the 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Post-Acute COVID-19 Syndrome with a site in Brazil, or all of them as a file.
02

Study summary

Different physical and mental morbidities such as pain, fatigue, depressed mood and cognitive impairment can be triggered by coronavirus infection. Transcranial direct current stimulation (tDCS), an easy-to-apply, non-pharmacological and safe technique, has been used to attenuate these symptoms caused by other diseases, and, therefore, it is expected that it can also attenuate them when generated by COVID-19. It is known that the persistent inflammatory state observed after COVID-19 would be related to the progression of these negative symptoms. As non-invasive brain stimulation can also attenuate acute and persistent inflammation, it can be estimated that tDCS can be a useful tool to recover immune function and reduce post-COVID-19 morbidity.

Read the detailed description

The aim of this study is to investigate if Direct Current Electrical Stimulation (tDCS) associated with motor and/or cognitive training is capable of reducing neuropsychiatric symptoms, as well as immune changes induced in COVID-19.

Volunteers will be randomized and allocated into four groups (Fatigue; Pain; Cognitive deficit and Depressed mood) and each group will be divided into two subgroups: 1) real tDCS + motor or cognitive training; and, 2) sham tDCS + motor or cognitive training according to each outcome. The volunteers will be evaluated in two aspect: immunometabolic evaluation (i) and clinical assessment (ii). The measures will pe performed in three moments: baseline (session 1); 72 hours after the last intervention (session 12) and follow up - 15 days after the last intervention (session 13).

(i) The immunometabolic evaluation will start with the participant's blood collection, after fasting for 8-12 hours, without having practiced intense physical activity and without drinking alcohol in the 24 hours prior to the collect. The blood will be allocated in 10 vacutainer tubes of 5ml containing EDTA for plasma separation, in 2 dry vacutainer tubes of 5ml for serum separation and 1 vacutainer tube of 5ml containing fluoride. In particular, 1 dry tube must rest for 1h, for subsequent BDNF analysis. 2 serum tubes, 2 plasma tubes and 1 fluoride tube should be centrifuged at 3,500 rpm for 15 minutes at 4°C, and the samples should be stored at -80°C for later analysis and the other fresh plasma tubes used (up to 2 hours after collection) for whole blood and PBMC stimuli.

Stimulation of whole blood with LPS, culture of peripheral blood mononuclear cells (PBMC), assessment of oxidative stress, assessment of adenine and LPS purine levels in plasma, analysis of immunophenotyping and apoptosis by flow cytometry, assessment of expression of purinoreceptors, mitochondrial assays in monocytes and T lymphocytes, evaluation of the generation of reactive oxygen species and quantification of several mediators by ELISA.

(ii) The clinical assessment will be performed using the following outcome measures:

COVID clinical situation - IInitially, modules 1 and 2 of the Case Report Form - CRF (Pcovid frameost COVID-19 CRF) of the Pan American Health Organization (PAHO) will be completed. Where module 1 comprises demographic data and clinical information related to the acute episode of COVID-19 and module 2 includes questions related to vaccination, occupational and functional status of the volunteer.

Fatigue - The Modified Impact of Fatigue Scale (MFIS) contains 21 items that analyze cognitive, physical and psychosocial issues in relation to fatigue, assessing the impact that is caused in the patient's life.

Pain - Brief Pain Inventory (BPI) assesses pain severity, impact of pain on daily function, pain location, pain medications, and amount of pain relief in the last 24 hours and last week; Visual Analog Scale (VAS) consists of a ruler numbered from 0 to 10 and divided into three parts, light, moderate and severe, with visual aid to facilitate the measurement of the patient's pain intensity.

Cognitive deficit - Montreal Cognitive Assessment (MoCA) instrument that quickly identifies cognitive declines in patients; FAS Test is a Verbal Fluency Test - Phonological Fluency Test that assesses verbal learning and the ability to produce words verbally; Random Number Generator (RNG test) assesses language and executive function; Digit span that will be used to assess the ability to focus, maintain attention, and mental manipulation. In the follow up, the CFL-test will be added to a verbal fluency test.

Depressed mood - Hospital Anxiety and Depression Scale (HADS) measures symptoms of anxiety and depression and consists of 14 items, seven for the anxiety subscale (HADS-Anxiety) and seven for the depression subscale (HADS-Depression); Brunel Mood Scale (BRUMS) used to quickly measure the patient's mood state.

Level of physical activity - The short version of IPAQ will be performed to identify if the volunteer has a life with active physical activities. It makes it possible to estimate the weekly time used for physical activities.

Vital signs - at the end of the scales, the signs of each patient will be measured: blood pressure, heart rate, respiratory rate and peripheral O2 saturation, parameters used to verify the hemodynamic status of the volunteer.

State of strength and effort - the handgrip strength test and perception of effort performed with the dynamometer will be used, quantitatively indicating the muscle strength of the hand and forearm.

Exercise capacity - the functional capacity and aerobic resistance of the participant will be evaluated through the 6-minute walk test. The test measures the distance that the volunteer covers in a period of 6 minutes walking at a stable speed.

At the end, a questionnaire of adverse effects of the evaluation will be carried out, containing information regarding any discomfort felt during the evaluation.

The intervention process will be carried out with Transcranial Direct Current Stimulation which will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor or cognitive training. For symptoms of pain and/or fatigue, the anode will be positioned in the area referring to the left primary motor cortex (C3, according to the EEG positioning system). For symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3). In both situations, the cathode will be positioned in the contralateral supraorbital region. In sham tDCS, the same parameters and setup as the real stimulation will be used, however, the application time will be 30 seconds, but the electrodes will be maintained for 30 minutes.

In motor training, the treadmill training protocol will last a total of 30 minutes and will be carried out during the application of tDCS. After positioning the tDCS electrodes, a cardiac monitor will be positioned on the individual to control HR. Before starting the protocol on the treadmill, the values of the perceived exertion scale (Borg) and HR should be noted.

Initially, the target HR for each part of the intervention will be determined. The formula by Tanaka et al., (2001) will be used to determine the maximum HR, with maximum HR = 208 - (0.7*age). For participants who use beta-blockers, the formula by Brawner et al., (2004) will be used, with maximum HR = 164 - (0.7*age).

The initial five minutes will be a warm-up. To achieve this, the target HR must be maintained at 50-60% of the maximum HR. The speed of the treadmill must be adjusted to maintain the HR within the pre-established target range. At five minutes, the Borg scale values, treadmill speed and HR must be noted. The central 20 minutes will be considered as the main part. To achieve this, the target HR must be maintained at 64-76% of the maximum HR. If the participant chooses to stop the treadmill session, the treadmill must be turned off and the participant must remain seated until the end of the tDCS application.

For cognitive training, carried out during tDCS, an n-Back task will be performed online in PsyToolkit (https://www.psytoolkit.org/). For a benefit on working memory learning curves. Performed for the outcomes of cognitive impairment and depressed mood. During the test, the volunteer will have to indicate which letter was projected by the application two letters ago. The system will show one letter followed by another, the volunteer must press the "space" key on the computer keyboard when the letter that was shown in the two positions above reappears.

The study will be carried out simultaneously in two research centers in Brazil: Laboratory of Applied Neuroscience (LANA), Federal University of Pernambuco (UFPE), Pernambuco, Brazil and at the Department of Physical Education, Faculty of Science and Technology - Campus Presidente Prudente (FCT/UNESP), São Paulo, Brazil.

03

Conditions studied

  • Long COVID

Keywords

  • Long COVID
  • Post-Acute COVID-19 Syndrome
  • Fatigue
  • Pain
  • Cognitive Dysfunction
  • Depression
  • Transcranial Direct Current Stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Long COVID-19 (>3 months)
  • The presence of at least one of the following symptoms, after diagnosed SARS-COV-2 infection:

Persistent pain Fatigue Depressed mood Cognitive impairment

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability
  • Historic of use or abuse of drugs or alcohol
  • Use of medications that may interfere with the study results (anti-inflammatories and antibiotics)
  • Metallic implant in skull and face
  • Implant in the central nervous system
  • Pacemaker
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Pain/fatigue tDCS real

    tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region. Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill.

    Device: Transcranial Direct Current Stimulation (tDCS) · Behavioral: Motor Training

  • Sham comparator
    Pain/fatigue tDCS sham

    tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region. Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill.

    Behavioral: Motor Training

  • Experimental
    Cognitive deficit and depressed mood tDCS real

    tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region. Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves.

    Device: Transcranial Direct Current Stimulation (tDCS) · Behavioral: Cognitive Training

  • Sham comparator
    Cognitive deficit and depressed mood tDCS sham

    tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region. Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves.

    Behavioral: Cognitive Training

Interventions

  • DeviceTranscranial Direct Current Stimulation (tDCS)

    tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.

    Also known as: non-invasive brain stimulation, neuroConn (Germany)

  • BehavioralMotor Training

    Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.

  • BehavioralCognitive Training

    an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.

06

What researchers measure

Primary outcomes

  1. Fatigue - Modified Fatigue Impact Scale (MFIS)

    The MFIS is a scale that contains 21 items that analyze cognitive, physical and psychosocial issues. The physical domain allows scores from 0 to 36, the cognitive domain from 0 to 40 and the psychosocial domain from 0 to 8. The total MFIS score is given by the sum of the three domains and varies from 0 to 84 points. Values below 38 correspond to the absence of fatigue, and above this value, the higher the score, the greater the individual's degree of fatigue.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  2. Pain measure - Brief Pain Inventory (BPI)

    assesses severity of pain, impact of pain on daily functions, location of pain, analgesics, and amount of pain relief in the past 24 hours and past week on an 11-point scale ranging from 0 (no pain/no interference) to 10 (the worst possible). Including a body diagram to assess the location of pain (item 2), scores range from 0 to 10 and are calculated as the average of the total items. A high score represents a high pain intensity or pain interference

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  3. Pain measure - Visual Analog Scale (VAS)

    consiste em uma régua numerada de 0 a 10 e dividida em três partes, leve, moderada e intensa, com auxílio visual para facilitar a mensuração da intensidade da dor do paciente.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  4. Cognitive deficit - Montreal Cognitive Assessment Instrument (MoCA)

    quickly identifies cognitive declines in patients with a maximum score of 30 (points), evaluates eight cognitive domains: 1. Executive function: with the Trail Making Test B (adapted - 1 point), phonemic verbal fluency (1 point) and abstraction verbal (2 points). 2. Visual-spatial ability: drawing the clock (3 points) and copying the cube (1 point). 3. memory: delayed recall of words 5 minutes (5 points). 4. Attention/5. Concentration/6. Working memory: digit memory (forward sense - 1 point), digit memory (backward sense - 1 point), sustained attention task (target detection - 1 point) and serial subtraction of 7 (3 points). 7. Language: naming 3 unfamiliar animals (3 points), repetition of 2 syntactically complex sentences - phonemic verbal fluency (above - 2 points). 8. Orientation: temporal (4 points) and spatial (2 points). It has a total score of 30 points. The cutoff score is 26 points, indicating the presence of cognitive deficit. Score above said is considered normal.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  5. Cognitive deficit - FAS Test

    is a Verbal Fluency Test/Phonological Fluency Test that assesses verbal learning and the ability to produce words verbally. The total score is given by adding up all correct words starting with the three letters.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  6. Cognitive deficit - CFL Test

    is a Verbal Fluency Test/Phonological Fluency Test that assesses verbal learning and the ability to produce words verbally. The total score is given by adding up all correct words starting with the three letters.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  7. Cognitive deficit - Random Number Generator

    Assesses language and executive function. Numbers are produced randomly when a previously recorded sound signal is heard. You must speak numbers from 1 to 10 without speaking sequences.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  8. Cognitive deficit - Digit span

    Used to assess the ability to focus, maintain attention, mental manipulation and memory. It consists of repeating the numbers said by the evaluator, where in the first phase they will be said in direct order (16 points) and in the second phase in reverse order (14 points). Together they add up to a maximum score of 30 points.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  9. Depressed mood - Hospital Anxiety and Depression Scale (HADS)

    measures symptoms of anxiety and depression divided into an anxiety subscale (HADS-Anxiety) and a depression subscale (HADS-Depression). Each question has a variable score from zero to four points, with 14 questions in total. From 0 - 7 points indicates anxiety and depression unlikely; 8 - 11 points indicate possible anxiety and depression and 12 - 21 points indicate probable anxiety and depression.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  10. Depressed mood - Brunel Mood Scale (BRUMS)

    Used to quickly measure a patient's mood using six subscales: tension, depression, anger, vigor, fatigue and confusion. It contains 24 questions that must be evaluated according to a scale of 0 to 4 points, each subscale has a score that can vary from 0 - 16.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

Secondary outcomes

  1. COVID clinical situation

    It will be carried out using the Case Report Form - CRF (Post COVID-19) from the Pan American Health Organization (PAHO). Using the first two modules, module 1 comprises demographic data and clinical information related to the acute episode of COVID-19 and module 2 includes questions related to vaccination, occupational and functional status of the volunteer. Based on these questionnaires, it is possible to identify the patient's status in their episodes of contagion with COVID-19 and the degree of support that was needed in each case, as well as the main symptoms and characteristics of the case.

    Time frame: pre-intervention

  2. Level of physical activity

    The short version of IPAQ will be performed to identify if the volunteer has a life with active physical activities. It makes it possible to estimate the weekly time used for physical activities.

    Time frame: pre-intervention

  3. State of strength and effort

    the handgrip strength test and perceived exertion performed with the dynamometer will be used to quantitatively indicate the muscle strength of the hand and forearm and to assess the level of effort exerted through the BORG scale.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  4. Exercise capacity - 6-minute walk test

    the participant's functional capacity and aerobic resistance will be evaluated through the 6-minute walk test. The test measures the distance that the volunteer covers in a period of 6 minutes walking at a steady speed.

    Time frame: pre-intervention, 72 hours after the last intervention and 15 days after completion.

  5. Immunometabolic evaluation

    will begin with the participant's blood collection. Stimulation of whole blood with LPS, culture of peripheral blood mononuclear cells (PBMC), evaluation of oxidative stress, evaluation of adenine and purine LPS levels in plasma, analysis of immunophenotyping and apoptosis by flow cytometry, evaluation of expression of purinoreceptors, mitochondrial assays in monocytes and T lymphocytes, evaluation of the generation of reactive oxygen species and quantification of several mediators by ELISA.

    Time frame: pre-intervention and 72 hours after the last intervention

07

Study locations

1 of 2 sites recruiting
  • Applied Neuroscience Laboratory-LANA
    Recife, Pernambuco 50740-560, Brazil
    Recruiting
    • Kátia Monte-Silva, PhD · Contactmonte.silvakk@gmail.com · +55 81 988631322
    • Patrícia Lopes, Graduation · Contactpatricia.flima@ufpe.br · +55 81 999897661
    • Kátia Karina Monte-Silva, PhD · Principal investigator
    • Patrícia Lopes, Graduation · Sub investigator
    • Lívia Shirahige, PhD · Sub investigator
    • Bárbara Sousa · Sub investigator
    • Ana Cecília · Sub investigator
    • Adriana Baltar, PhD · Sub investigator
    • Rodrigo De Mattos, Master · Sub investigator
    • Gabriel Barreto, Master · Sub investigator
  • Department of Physical Education, Faculty of Science and Technology
    Presidente Prudente, São Paulo 19060-900, Brazil
    Not yet recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jul 2024, 10 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 10 months is below that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2023
First posted
Oct 10, 2023
StartActual
Aug 25, 2023
Primary completionEst.
Jul 1, 2024
CompletionEst.
Sep 28, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06074848
Collaborators
São Paulo State University
Responsible party
Kátia Monte-Silva (Investigador principal, Universidade Federal de Pernambuco) — Principal investigator
First posted
Oct 10, 2023
Start date
Aug 25, 2023
Primary completion
Jul 1, 2024 (estimated)
Completion
Sep 28, 2024 (estimated)
Last update
Apr 24, 2024

Study contacts

Kátia Monte-Silva, PhD
Contact
monte.silvakk@gmail.com
+55 81 988631322
Patrícia Lopes, graduation
Contact
patricia.flima@ufpe.br
+55 81 999897661
Patrícia Lopes, graduation
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Lívia Shirahige, PhD
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Bárbara Sousa
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Ana Cecília
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Adriana Baltar, PhD
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Rodrigo De Mattos, Master
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Gabriel Barreto, Master
study chair · Laboratory of Applied Neuroscience, Federal University of Pernambuco
Fábio Santos de Lira, PhD
study chair · Department of Physical Education, Faculty of Science and Technology - Presidente Prudente Campus
Fabrício Oliveira Souto, PhD
study chair · Universidade Federal de Pernambuco
Kátia Monte-Silva, PhD
study director · Laboratory of Applied Neuroscience, Federal University of Pernambuco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion